Presentation TCT 2017

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Presenter: Michael J. Reardon

October 30, 2017

REGISTER for free or LOG IN to view this content

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing – TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Structural Heart

Presentation

TCT 2017

Aortic Valve

Up Next

Presentation TCT 2017

Viewpoint #2: Not So Fast! GARY and Other Studies Indicate an Important Role for Surgery in Intermediate-risk Patients

Presenter: Thomas Walther

October 30, 2017

More slides +

Presentation TCT 2017

The UK All-comer TAVI Study

Presenter: Neil E. Moat

October 30, 2017

Presentation TCT 2017

The PARTNER 3 Low-risk Trial

Presenter: Michael J. Mack

October 30, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.